Arecor Therapeutics (LON:AREC) Announces Quarterly Earnings Results

Arecor Therapeutics (LON:AREC) released its quarterly earnings data on Thursday. The company reported GBX (8) earnings per share for the quarter, Digital Look Earnings reports. Arecor Therapeutics had a net margin of 38.74% and a return on equity of 14.26%.

Arecor Therapeutics Trading Down 3.3%

Shares of Arecor Therapeutics stock traded down GBX 2.40 during trading on Friday, reaching GBX 70.10. The company’s stock had a trading volume of 41,696 shares, compared to its average volume of 24,759. The company has a quick ratio of 6.24, a current ratio of 4.35 and a debt-to-equity ratio of 1.52. Arecor Therapeutics has a 52-week low of GBX 56 and a 52-week high of GBX 95. The firm’s 50-day moving average is GBX 71.73 and its two-hundred day moving average is GBX 67.95. The company has a market cap of £26.47 million, a price-to-earnings ratio of 35.05 and a beta of -0.18.

Arecor Therapeutics Company Profile

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.